Acute ischaemic stroke, the most common type of stroke, occurs when the blood supply to part of the brain is blocked by either a blood clot in a brain vessel or atherosclerosis (fatty deposits or plaques lining vessel walls). A stroke can lead to disability or even death and always requires quick, acute treatment. Boehringer Ingelheim led the way in stroke care by developing the only licensed blood clot dissolving treatment (thrombolytic) for acute ischaemic stroke therapy, which is now used in stroke centres worldwide. Boehringer Ingelheim also sponsors the angels initiative: a programme that helps doctors to set up and optimise acute stroke networks with the support of local and international stroke societies.

Latest Articles


Telling my story...AF & DVT/PE Patient Voices

Telling My Story is a video series featuring stories from across the world from patients with atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE).
Angels Initiative

The Angels Initiative

The Angels Initiative is a unique healthcare initiative to improve acute care for people who have just suffered a stroke